SBIR/STTR Research Award
MRNA VACCINE DEVELOPMENT
Award amount
$594,566Program and phase
SBIR · Phase IAward year
2024Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- Flag Bio, Inc
- Proposal award date
- Not reported
- Contract end date
- Not reported
- UEI
- LZTAN53LY9V9
- Solicitation number
- PHS-2024-1
- Topic code
- 128
Research abstract
The contractor will develop mRNAFlag as a vaccine adjuvant. mRNAFlag is an mRNA transcript that encodes for the deimmunized TLR5 agonist GP532. mRNAFlag would be developed within the context of an influenza mRNA vaccine, using an A/California/07/2009(H1N1) hemagglutinin in an LNP formulation used by Moderna for its SARS-CoV-2 vaccine.
Technology keywords
Not reported
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- Development of a VesiVax TLR7 Formula as an Effective Adjuvant
- DEVELOPMENT OF COVALENTLY BOUND HYALURONIC ACID AS AN ADJUVANT FOR MULTIVALENT LYME DISEASE VACCINE